Cargando…
Should GDMT be prioritized over revascularization in new onset HFrEF? Potential lessons from the REVIVED-BCIS2 and STRONG-HF trials
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Frontiers Media S.A.
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10291608/ https://www.ncbi.nlm.nih.gov/pubmed/37378411 http://dx.doi.org/10.3389/fcvm.2023.1193226 |
| _version_ | 1785062721149992960 |
|---|---|
| author | Dixit, Neal M. Amsterdam, Ezra A. |
| author_facet | Dixit, Neal M. Amsterdam, Ezra A. |
| author_sort | Dixit, Neal M. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10291608 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Frontiers Media S.A. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-102916082023-06-27 Should GDMT be prioritized over revascularization in new onset HFrEF? Potential lessons from the REVIVED-BCIS2 and STRONG-HF trials Dixit, Neal M. Amsterdam, Ezra A. Front Cardiovasc Med Cardiovascular Medicine Frontiers Media S.A. 2023-06-12 /pmc/articles/PMC10291608/ /pubmed/37378411 http://dx.doi.org/10.3389/fcvm.2023.1193226 Text en © 2023 Dixit and Amsterdam. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) (https://creativecommons.org/licenses/by/4.0/) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
| spellingShingle | Cardiovascular Medicine Dixit, Neal M. Amsterdam, Ezra A. Should GDMT be prioritized over revascularization in new onset HFrEF? Potential lessons from the REVIVED-BCIS2 and STRONG-HF trials |
| title | Should GDMT be prioritized over revascularization in new onset HFrEF? Potential lessons from the REVIVED-BCIS2 and STRONG-HF trials |
| title_full | Should GDMT be prioritized over revascularization in new onset HFrEF? Potential lessons from the REVIVED-BCIS2 and STRONG-HF trials |
| title_fullStr | Should GDMT be prioritized over revascularization in new onset HFrEF? Potential lessons from the REVIVED-BCIS2 and STRONG-HF trials |
| title_full_unstemmed | Should GDMT be prioritized over revascularization in new onset HFrEF? Potential lessons from the REVIVED-BCIS2 and STRONG-HF trials |
| title_short | Should GDMT be prioritized over revascularization in new onset HFrEF? Potential lessons from the REVIVED-BCIS2 and STRONG-HF trials |
| title_sort | should gdmt be prioritized over revascularization in new onset hfref? potential lessons from the revived-bcis2 and strong-hf trials |
| topic | Cardiovascular Medicine |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10291608/ https://www.ncbi.nlm.nih.gov/pubmed/37378411 http://dx.doi.org/10.3389/fcvm.2023.1193226 |
| work_keys_str_mv | AT dixitnealm shouldgdmtbeprioritizedoverrevascularizationinnewonsethfrefpotentiallessonsfromtherevivedbcis2andstronghftrials AT amsterdamezraa shouldgdmtbeprioritizedoverrevascularizationinnewonsethfrefpotentiallessonsfromtherevivedbcis2andstronghftrials |